Billerica, Massachusetts, July 18, 2016 — MilliporeSigma today is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges and helping accelerate development of new therapies.
Formerly known as biomanufacturing science training centers, the new state-of-the art M Lab™ Collaboration Centers provide a simulated manufacturing environment for experiments, troubleshooting and problem solving, in a non-GMP setting, that fosters education and full end-to-end process development support. Customers participate in product demonstrations, hands-on training and proof-of-concept work, as well as apply best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer.
“These centers have been an important resource for our customers and the biopharma industry for more than two decades,” said Udit Batra, Member, Executive Board, Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma. “Now reimagined and reengineered as M Lab™ Collaboration Centers, we have taken our industry-leading concept to the next level. We are creating unique and inspiring settings where customers can explore new ways to increase productivity and improve processes in close collaboration with our team of experts.”
MilliporeSigma unveiled its first remodeled center in Tokyo, Japan on June 29, 2016. The network, established in 1995, will also include locations in Brazil, China, France, India, Singapore, South Korea and the United States with formal relaunch of centers around the world taking place throughout the remainder of 2016 and 2017.
Each M Lab™ Collaboration Center will welcome customers and collaboration partners from government, academia, regulatory bodies and industry associations, offering application best practices and knowledge sharing tailored to address the specific needs of local pharmaceutical manufacturers. Customers will have access to sizing and simulation tools and methodologies as well as analytical and modeling support and customer education programs.
To learn more about the M Lab™ Collaboration Centers and view videos of MilliporeSigma’s facilities, visit www.emdmillipore.com/mlab.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA of Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD performance materials.